Hints and tips:
...The move is one of the boldest steps yet by chief executive Vas Narasimhan to focus Novartis on more lucrative drugs that include those targeting cancer and rare diseases....
...Letter in response to this article: Why R&D is the number you want / From Néstor Enrique Cruz, Falls Church, VA, US...
...Linh’s movie, Em va Trinh, a biopic about Trinh Cong Son, who is sometimes called his country’s Bob Dylan, is No. 1 at the Vietnamese box office today....
...john.gapper@ft.com Letters in response to this column: Mankind’s addiction to growth is only one climate challenge / From Madhav Acharya, Vienna, VA, US What would the father of streamlining have said...
...Selling its generic drugs business Sandoz — a possibility mooted by boss Vas Narasimhan on Tuesday — would be the final step in creating a drugs giant narrowly focused on innovative medicines....
...The futuristic plane, dubbed the VA-X4, will have a range of more than 100 miles and be able to travel near-silently at speeds of more than 200mph....
...Bert Ely Ely & Company Inc, Alexandria, VA, US...
...Eurasia (For José Andrés) 960 Laskin Road, Virginia Beach, VA 23451 Virginia Beach fried oysters Ravioli with ramps (an Appalachian wild leek) Beef brisket sandwich with fries Soft-shell crab Glass...
...A proposal by the Federal Reserve could force large foreign banks in the US to hold more liquid assets, Novartis CEO Vas Narasimhan says the Swiss drugmaker is limiting its spending on takeovers and the...
...Vas Narasimhan, a social media-friendly medic who became chief executive in February last year, is focusing on innovative medicines....
...Vas Narasimhan, chief executive of the Swiss drugmaker, said that Richard Francis, who has run Sandoz for the past five years, had “decided that for personal reasons he cannot commit to stay with Sandoz”...
...Swiss drugmaker Novartis plans to spin off its Alcon eyecare unit, possibly worth as much as $25bn, as new chief executive Vas Narasimhan pushes ahead with his focus on core medicines businesses....
...Since taking the helm in February, Vas Narasimhan has moved quickly to reshape the company, selling its 36.5 per cent stake in a consumer joint venture with GlaxoSmithKline and announcing plans to spin off...
...Vas Narasimhan, the pharmaceuticals group's new boss said: We continued our transformation this quarter to become a more focused medicines company....
...Novartis has sold its stake in its consumer health joint venture with GlaxoSmithKline to its British rival for $13bn in an early move by Vas Narasimhan, the Swiss pharmaceuticals group's new boss, to focus...
...When Novartis announced on Tuesday the sale to GlaxoSmithKline of its 36.5 per cent stake in their consumer health joint venture for $13bn, it marked an unexpectedly early and decisive move for Vas Narasimhan...
...Last month, Novartis announced 41-year-old Vas Narasimhan, its head of drug development, would succeed Mr Jimenez as chief executive early next year....
...“We believe fundamentally that all the other Alzheimer’s trials in the industry are intervening too late,” says Vas Narasimhan, chief executive-elect of Novartis, which is studying its medicine in healthy...
...to intellectual property / From Dr Richard Rohwer, San Diego, CA, US To SMEs, patent trolls are an existential threat/ From Gary Shapiro, President and CEO, Consumer Technology Association, Arlington, VA...
...“The level of pre-treatment and controlling for that is something we want to be cognisant of, because we want to ensure we have a consistent set of baseline patients to evaluate,” says Vas Narasimhan, global...
...“We look forward to supporting clinical stage breakthrough innovations in partnership with Medicxi and Verily,” said Vas Narasimhan, global head of drug development at Novartis....
...“We’ve been able to treat patients successfully in Australia and Japan out of our Morris Plains facility in New Jersey because we can freeze and hold for 30 days and use them any time,” says Vas Narasimhan...
...“This could meaningfully affect sales of VAs and FIAs in the near term,” said Beth Campbell, an S&P credit analyst, of the new regime, which begins next April....
...Stock market downturns also make variable annuities (VAs) — popular retirement-income products in the US — harder to manage....
International Edition